Fulvestrant

Hereditary Disease

Borstkanker Onderzoek GroepSmall moleculePhase 2Active

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 95/ 100

Competitive context

9 Active assets in the Hereditary Disease cohort.

Asset / Sponsor	Phase	Rating
Dexasone Intergroupe Francophone du Myelome	Phase 3	BB
Aoc 1044 Avidity Biosciences, Inc.	Phase 3	B
Zeleciment Rostudirsen Dyne Therapeutics	Phase 3	B
Nexiguran Ziclumeran Intellia Therapeutics	Phase 3	B
Pomalidomide Intergroupe Francophone du Myelome	Phase 2	CCC

View all 15 →

Same molecule, other indications

Fulvestrant is also rated in:

hormone receptor-positive breast cancerActive

BB

Indicative · Phase 4

70 / 100

breast cancerActive

BB

Indicative · Phase 4

69 / 100

invasive breast carcinomaActive

BB

Indicative · Phase 2

68 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.